$SLDB

Solid Biosciences Inc.

Solid Biosciences is a life sciences company developing gene therapy candidates for rare neuromuscular and cardiac diseases. Its pipeline includes SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich’s ataxia, SGT-501 for CPVT, SGT-601 for TNNT2-mediated dilated cardiomyopathy, and earlier-stage cardiac candidates. The company also develops platform technologies, including capsid libraries and genetic regulators, and collaborates on cardiac gene therapy research. Solid Biosciences’ candidates are primarily gene transfer products, designed to deliver functional genes to patients’ cells. It aims to develop treatments and license technologies, including its POLARIS-101 capsid, to companies, institutions and academic labs. Its candidates are in various stages of development, and it relies on third-party manufacturers for supply of SGT-003, SGT-212 and SGT-501. Solid Biosciences is headquartered in Charlestown, Massachusetts.

1
0
0
—
$25K
Brooks Gabriel
100%
See all $SLDB insider activity →

Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Updates

Solid Biosciences reported Q3 2026 results, highlighting progress in its Duchenne and Friedreich’s ataxia programs. SGT-003 was well tolerated in 53 participants, with an FDA meeting scheduled for Q4 2026 to discuss accelerated approval. SGT-212 dosed five participants in its Phase 1b trial. The company had $348.9M in cash as of Q3 2026, expecting funding into 2028. Q3 net loss was $53.9M, up from $45.8M in Q3 2025.

SLDB sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning SLDB (Solid Biosciences Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.

Recent SLDB coverage spans financial news, earnings and regulation.

In the last 30 days, SLDB insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($25K). The most active reporter was Brooks Gabriel, Chief Medical Officer, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving SLDB

AlphAI scores every news story that mentions SLDB with an AI model for sentiment and relevance, and aggregates insider trades from Solid Biosciences Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $SLDB

Score

Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Updates

Solid Biosciences reported Q3 2026 results, highlighting progress in its Duchenne and Friedreich’s ataxia programs. SGT-003 was well tolerated in 53 participants, with an FDA meeting scheduled for Q4 2026 to discuss accelerated approval. SGT-212 dosed five participants in its Phase 1b trial. The company had $348.9M in cash as of Q3 2026, expecting funding into 2028. Q3 net loss was $53.9M, up from $45.8M in Q3 2025.

Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), LeonaBio (LONA) and Solid Biosciences (SLDB)

Analysts from Piper Sandler and Cantor Fitzgerald maintained Buy ratings on NeoGenomics (NEO), LeonaBio (LONA), and Solid Biosciences (SLDB). NeoGenomics has a $21.00 target, LeonaBio a $20.00 target, and Solid Biosciences a $26.00 target. Consensus ratings are Moderate Buy for NEO and Strong Buy for LONA and SLDB, with respective average targets of $18.33, $17.33, and $19.17.

$SLDBLowShareholder vote

Solid Biosciences Inc. (SLDB): Submission of Matters to a Vote of Security Holders

Solid Biosciences Inc. (SLDB) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001707502 false 0001707502 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10,

Solid Biosciences (SLDB) Receives Orphan Drug Designation for SG

Solid Biosciences Inc. (SLDB) has received orphan drug designation from the European Commission for SGT-003, its investigational treatment for Duchenne muscular dystrophy. This designation provides significant benefits like market exclusivity in the EU and regulatory assistance, highlighting the company's commitment to rare disease therapies. Despite this positive development, the company holds a low GF Score™ of 39 and has experienced significant insider selling, which investors should consider.

Related tickers